Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Research of Double-positive Circulating Cells (Tumor Marker / CD45+) in Several Types of Metastatic Cancers

NCT06967961 is registered in ClinicalTrials.gov with Institut Claudius Regaud as lead sponsor.

NCT NCT06967961
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06967961 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Research of Double-positive Circulating Cells (Tumor Marker / CD45+) in Several Types of Metastatic Cancers
Lead sponsor
Institut Claudius Regaud
Phase
Not applicable
Overall status
Recruiting
Start date
July 23, 2025
Completion date
July 23, 2029
Enrollment
450 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

adenocarcinoma of endometrium, cervical carcinoma, cutaneous melanoma, nonseminomatous germ cell tumor, prostate adenocarcinoma, renal cancer, seminomatous germ cell tumor, soft tissue sarcoma (sts), upper aerodigestive tract carcinoma, urothelial carcinoma